| Prev Close | 298.85 |
| Open | 300.60 |
| Day Low/High | 299.35 / 304.92 |
| 52 Wk Low/High | 195.50 / 314.00 |
| Volume | 2.87M |
Eli Lilly and Company (LLY)
302.60
3.75
1.25
NYSE
| Exchange | NYSE |
| Shares Outstanding | 950.16B |
| Market Cap | 272.00B |
| P/E Ratio | 33.79 |
| Div & Yield | N.A. (N.A) |
Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
Eli Lilly Could Rally After Passing the Test
Successful tests of a rising 200-day moving average line can be great entry points for longs.
Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
A Healthy Dose of Vaccine and Pharmaceutical Plays
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Here's How I'm Trading XBiotech
Do these shares get back to the 2020 highs that were reached back in January?
Jim Cramer: Betting Against Science Is a Mug's Game
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.
Jim Cramer: Handicapping the Major Covid-19 Vaccine Makers
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Charting the Stocks of 3 Covid Treatment Companies
Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.
7 Drug Stocks With the Right Medicine for Investors
These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.
Eli Lilly Shoots Up Following Drug Study
Potential for a new blockbuster breast cancer treatment is eyed as possible game changer, so let's see the charts and indicators for a new target.
Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
A Triangle Formation on Drug Maker Eli Lilly Is Ready for an Upside Breakout
The question is whether you want to buy before the breakout or after the breakout?
This Chart Pattern Hints at a Bullish Future
The bullish reversal pattern is appearing not just in single names, but also in whole sectors.
I Like What Eli Lilly Is Doing, but Have All the Horses Left the Barn?
Here are my thoughts on the quarter and trading the stock.
Employment Figures, Trading Thoughts, and 'Busting a Move'
Watching first-time jobless claims and trading volume, plus some thoughts on defense names like Raytheon and Lockheed Martin, and tech names like Lam Research.
Eli Lilly Surges to a New High and a New Price Target Opens Up
An inspiring performance.
You Can Gild the Lilly
Our technical strategy says that Eli Lilly can be bought on strength over $144, as the name looks more attractive along with others in the health care sector.
3 Strong Long-Term Buys for Uncertain Times
These pharmaceutical names have what it takes amid the current crisis and for the long run.
I Have More Hope for Eli Lilly's Research Partnership Than Its Charts
LLY is entering into a new partnership with AbCellera Biologics in an attempt to develop an antibody for Covid-19.
Jim Cramer: Do You Really Want to Sell Now?
The answer to that question depends on several factors, so let's break them down.
The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon
It's no secret that the Fed would like to get out of the short-term repo business.
Adding to My Biotech Positions When Profit-Taking Hits
Here's my strategy which has worked particularly well.
All-Time Highs
It is nice to once again be sitting in for Doug Kass this Friday at the Daily Diary. I will be coming to you from a Starbucks in downtown Miami this morning, as the internet in my building has decided to opt for a three-day weekend. Oh, the perils o...
Biotech's Big Week Finds a Big Winner in Adaptimmune
The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.
4 Favorite Biotech Stock Picks for 2020
The Medical Technology Stock Letter's top pick rose 357% in 2019.
3 Powerhouse Pharma Stock Favorites
These healthcare stalwarts look attractive for growth and income.
Eli Lilly Has the Base to Support a New Rally
Shares of the pharmaceutical company received a quant upgrade Monday.
